{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 53,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes legend for regional sales and collaboration revenue categories.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/18",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.03,
        "y": 0.235
      },
      "kind": "chart",
      "text": "Product sales",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d83ab45-649b-4523-a679-4ddf6d336601",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.66,
        "y": 0.235
      },
      "kind": "chart",
      "text": "Collaboration revenue",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac4b8a8f-b4f4-4e41-8fbd-907bc74b3858",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.35,
        "y": 0.235
      },
      "kind": "list",
      "text": "Growth in all regions: US +24%, Europe +35%, ERoW +28%, EM +41%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12b7c68a-37a1-4839-898c-dc6bf7b74f5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "PARP = poly ADP-ribose polymerase; OC = ovarian cancer; mBC = metastatic breast cancer; mCRPC = metastatic castration resistant prostate cancer; HRD = homologous recombination deficiency. 1. at actual exchange rates. Lynparza is being developed and commercialised in collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c876fe3-f10e-426e-ba90-ec5211d00c71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "The globally leading PARP inhibitor across four tumour types",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4a7cfa7-17e9-4ce0-b295-e4ba4a1922b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Lynparza",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f4282ed-2004-48b0-b185-b0f4f1da7bf9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e1c98b8b-502c-44c3-8a4f-5b036b65dd56",
      "evidence": "The deck presents a golden circle narrative, highlighting why AstraZeneca is positioned for growth, how they will achieve it, and what the results are",
      "position": 0,
      "objective": "Why AstraZeneca is positioned for growth",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 20,
      "from": 17,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4aeca240-ea18-44f3-aff0-4b3d61131237",
      "evidence": "The deck presents opportunities for quick wins and big bets, such as strong congress presence and launch into GI cancers",
      "position": 1,
      "objective": "Strong congress presence and launch into GI cancers",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.5,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}